OCUL Earnings

OCUL reported its earnings on 2026-05-05, showcasing a revenue of 10.79M against an estimate of 12.73M, resulting in a -15.28% surprise. The EPS was -0.41, surpassing the expected -0.32 by -28.12%. The stock experienced a -0.61% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following OCUL's earnings announcement on 2026-05-05, the stock price moved by -0.61% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, OCUL's stock price tends to shift by an average of -0.93% in the 10 days leading up to earnings and 1.62% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate OCUL's annual revenue to reach 15.12M, while the EPS is projected at -0.34. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between OCUL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, OCUL's stock price typically moves by -0.93% in the 10 days before its earnings and 1.62% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.34 and revenue of 15.12M.

The earnings call shows mixed signals: while there is strong enthusiasm from retina specialists and positive retention rates in trials, there are notable risks regarding regulatory approval, commercialization readiness, and financial sustainability. The company is pleased with FDA collaboration, but lacks specific timeline disclosures, creating uncertainty. The market cap of $1 billion suggests moderate volatility, leading to a neutral stock price prediction in the short term.